ScinoPharm Taiwan Ltd. offers process research and development and the production of active pharmaceutical ingredients. The Company provides services to pharmaceutical industries globally.

Board Of Directors Resolved To Acquire Privately
Placed Common Shares Of Handa Pharmaceuticals, Inc.

The Board Of Directors Approved The Capital
Expenditure Budget

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Scinopharm Taiwan (1789 TT)

Board Of Directors Resolved To Acquire Privately Placed Common Shares Of Handa Pharmaceuticals, Inc.

The Board Of Directors Approved The Capital Expenditure Budget

Scinopharm To Attend The Online Investor Conference Held By Masterlink Securities

To Announce The Company'S 2024 Q3 Consolidated Financial Report Approved By The Board Of Directors

To Announce The Company'S Board Meeting Date Of 2024 Q3 Consolidated Financial Report

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)